FDA Warns Against Compounded Moxifloxacin Injections
FDA received case reports of TASS (Toxic Anterior Segment Syndrome) following intraocular administration of compounded drugs using moxifloxacin as a bulk drug substance, as well as reports associated with the intraocular administration of repackaged and/or diluted FDA-approved moxifloxacin drugs.
Dr. David Hussong explains the FDA’s recent alert to health care professionals of risks associated with intraocular use of compounded moxifloxacin.
Learn more about this on the FDA website through the link below:
- 9 Vaccine Makers Pledge, Myocarditis Issue, and More - September 17, 2020
- FDA Warns Against Compounded Moxifloxacin Injections - August 26, 2020
- Dangerous Hand Sanitizers on the Market – FDA Recalls - August 18, 2020